Wilson Therapeutics Appoints Chair
This article was originally published in Scrip
Wilson Therapeutics AB., a privately held pharmaceutical company, has appointed Andrew Kay chair of its board of directors. Hugh Rienoff, the company's previous chair, will continue to advise the company as a consultant. Kay is currently advisor and chair to various biotech companies and most recently was CEO of Algeta, a publicly traded oncology company acquired by Bayer. He was previously global head of marketing and sales at Novartis, vice-president of marketing US at Zeneca and also held commercial positions in Europe with AstraZeneca, Eli Lilly, Sandoz and Boots.